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Abstract
The etiology of multiple sclerosis (MS) is still unclear. The immuno-pathogenic phenomena leading to neurodegeneration
are thought to be triggered by environmental (viral?) factors operating on predisposing genetic backgrounds. Among the
proposed co-factors are the Epstein Barr virus (EBV), and the potentially neuropathogenic HERV-W/MSRV/Syncytin-1
endogenous retroviruses. The ascertained links between EBV and MS are history of late primary infection, possibly leading
to infectious mononucleosis (IM), and high titers of pre-onset IgG against EBV nuclear antigens (anti-EBNA IgG). During MS,
there is no evidence of MS-specific EBV expression, while a continuous expression of HERV-Ws occurs, paralleling disease
behaviour. We found repeatedly extracellular HERV-W/MSRV and MSRV-specific mRNA sequences in MS patients (in blood,
spinal fluid, and brain samples), and MRSV presence/load strikingly paralleled MS stages and active/remission phases. Aim of
the study was to verify whether HERV-W might be activated in vivo, in hospitalized young adults with IM symptoms, that
were analyzed with respect to expression of HERV-W/MSRV transcripts and proteins. Healthy controls were either EBV-
negative or latently EBV-infected with/without high titers of anti-EBNA-1 IgG. The results show that activation of HERV-W/
MSRV occurs in blood mononuclear cells of IM patients (2Log10 increase of MSRV-type env mRNA accumulation with
respect to EBV-negative controls). When healthy controls are stratified for previous EBV infection (high and low, or no anti-
EBNA-1 IgG titers), a direct correlation occurs with MSRV mRNA accumulation. Flow cytometry data show increased
percentages of cells exposing surface HERV-Wenv protein, that occur differently in specific cell subsets, and in acute disease
and past infection. Thus, the data indicate that the two main links between EBV and MS (IM and high anti-EBNA-1-IgG titers)
are paralleled by activation of the potentially neuropathogenic HERV-W/MSRV. These novel findings suggest HERV-W/MSRV
activation as the missing link between EBV and MS, and may open new avenues of intervention.
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Introduction
Multiple sclerosis (MS) is a chronic neurological disease, which
usually begins in early adulthood. It causes repeated unpredictable
bouts of motor disorders, partial paralysis, sensory abnormalities
and visual impairment, with demyelination and gliosis, various
degrees of axonal pathology and episodic or progressive neuro-
logical disability. The aetiology is unknown and complex, but
results from an inflammatory process that, among other effects,
attacks and destroys oligodendrocytes, the cells that form the
myelin sheaths around axons in the brain and spinal cord [1]. The
immunopathogenic phenomena leading to MS are thought to be
triggered by environmental (viral?) factors operating on a
predisposing genetic background.
Several viruses have been proposed as co-factors that may
contribute to MS risk [2–3], by direct (acute or persistent) infection
of the brain, or peripheral infection activating cross-reactive T-
cells, acting against nerve myelin [4]. The most consistent studies
(and confirmed by independent groups) for a potential virus
involvement in MS exist for the Epstein Barr virus (EBV) [5–8],
and for two members of the W family of human endogenous
retroviruses (HERV-W): MSRV (MS associated retrovirus), and
ERVW-1, an element expressing only the env protein, named
Syncytin-1, as reviewed in [9–13].
The MSRV element (MS-associated retrovirus) is the first
known member of the HERV-W family [14]; it has been detected
and purified from cells of MS patients, as free virus-like particles,
carrying RT activity and an RNA genome with terminal repeats,
gag, pol and env regions. The other HERV-W member related to
MS is an element located on chromosome 7q21–22, that has
inactivating mutations in the gag and pol genes and is not able to
form virus-like particles [15]. The env product of ERVW-1 has
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been named syncytin-1, since it is produced by placental
trophoblasts and causes their fusion, to form the syncytial layer
during pregnancy [16]. The syncytin-1 protein can be found
intracellularly and on the plasma membrane, but has not been
detected extracellularly, nor its RNA sequence in virus-like
particles [10].
Independent studies have shown that MSRVenv and syncytin-1
proteins share several potentially pathogenic, biological features,
as induction of T mediated immunopathology, of pro-inflamma-
tory cytokines and T-cell responses, with polyclonal expansion, as
reviewed in [10–11], and have been shown to cause neurotoxic
effects in vitro and in humanized or transgenic animal models
[15,17]: they may cause neuroinflammation, neurodegeneration,
alterations of the immune system and stress responses; both have
been suggested as co-factors triggering the immuno-pathogenesis
of MS. Expression of HERV-W/MSRV/syncytin-1 occurs in
astrocytes of MS lesions of the brain [15,18–20], as well as in
endothelial and microglial cells [21]. In a mouse model,
oligodendrocytes (which produce the myelin sheath of the nerve)
were shown to be sensitive to syncytin-mediated release of redox
reactants from astrocytes [15].
Studies from our group found repeatedly retrovirus-like MSRV
particles and MSRV-specific mRNA sequences in MS patients (in
blood, spinal fluid, and brain samples), and MRSV presence/load
strikingly paralleled disease behaviour. A multicentre study of MS
patients and controls from different European areas showed that
MSRV presence and load in blood and spinal fluid was
significantly associated to MS in all ethnic groups [22]. Direct
parallelisms were observed between MSRV positivity/load (in
blood, spinal fluid, and brain samples) and MS temporal and
clinical stages, as well as active/remission phases; moreover
MSRV positivity of spinal fluids increased with MS duration [23].
Notably, MSRV presence in spinal fluids of early MS cases was
related to worse prognosis in the next ten years: starting from
comparable conditions, after three [24], six [25], and ten years
[26], mean disability, annual relapse rate, therapy requirement
and progression to secondary-progressive MS were significantly
higher in patients starting with MSRV-positive spinal fluids. When
we monitored MS patients receiving treatment, a major reduction
of HERV-W/MSRV/syncytin-1 was detected in patients under-
going efficacious, current therapies [13,27]. Notably, in a
longitudinal evaluation, a patient, after initial clinical and
virological benefit, had MSRV rescue, preceding strong disease
progression and therapy failure [27]. From the above findings, we
proposed that evaluation of plasmatic MSRV could be considered
the first prognostic marker for the individual patient, to monitor
disease progression and therapy outcome. This possibility is
reinforced by the study of patients with optic neuritis, a disease
frequently prodromic to MS: MSRV positivity of patients was
found significantly higher than that of pathological controls, and
the conversion to full-blown MS in the next 20 months occurred
only among MSRV-positive patients [28]. In line with our
findings, an independent 1-year follow up study of MS patients
observed significant decreases in anti-HERV-Wenv and anti-
HERV-Henv antibody reactivity as a consequence of IFN-b
therapy, closely linked to efficacy of therapy/low disease activity
[29]. Other HERVs were reported to be activated in MS patients
[3,9,12]. However none of them, but HERV-W, has been shown
to exert potentially (neuro)pathogenic properties.
As for EBV, seroepidemiological studies have provided
substantial support for the association between EBV and MS
[5–8,30–31]. The risk of MS is low in EBV-negative individuals
[32–34], and increases several folds following EBV infection,
particularly if the EBV infection occurs in late adolescence or
adulthood, when the infection is symptomatic. Indeed, in 35 to
50 per cent of the cases, the delayed EBV primary infection causes
infectious mononucleosis (IM), that has been associated with a
two-to-four fold increased risk of MS, [5,35–38]. There is also an
increased risk of MS among EBV-positive children [39]. A meta-
analysis showed an association between the appearance of anti-
EBV antibodies and the MS onset, 5–20 years later [7]; another
one reported that the relative risk of MS for a past history of IM is
2.17 [8]. In addition, elevated serum titers of pre-onset anti-EBNA
antibodies have been associated with an increased risk of MS
[35,40]. A recent meta-analysis of all data published from from
1960 to 2012 showed a significant OR for sero-positivity to anti-
EBNA (EBV nuclear antigens) IgG and anti-VCA IgG in MS
cases, but not for anti-EA IgG sero-positivity [6]. Notably, high
levels of anti-EBNA IgG antibody are established risk factors for
MS [35].
There is convincing epidemiological evidence that late EBV
primary infection/seroconversion is a risk factor for MS develop-
ment, nevertheless, the relationship between EBV and MS
pathogenesis remains elusive [4,30–31]. No studies have found
yet evidence of EBV expression specific to MS, and currently there
is no consensus in establishing whether there is a presence of EBV-
infected cells in the central nervous system (CNS) of MS
patients[30,41–42]. Therefore, it remains to be determined
whether EBV would continue to play a role after disease initiation.
Several potentially pathogenic mechanisms explaining an EBV
causative role for MS, yet very speculative, have been proposed, as
recently reviewed [4,30]; they include molecular mimicry (gener-
ation of autoreactive T cells are primed against EBV, but cross-
reacting with CNS antigens), and generation of EBV-infected
autoreactive B cells (that would seed the target organ expressing
the autoantigen and produce autoantibodies and costimulatory
signals to autoreactive T cells).
Recently, we showed that the binding to the plasmamembrane
of EBVgp350, the major envelope protein of EBV, is sufficient to
activate the potentially immunopathogenic and neuropathogenic
HERV-W/MSRV/syncytin-1, in cells that may be involved in
MS pathogenesis, deriving from blood and brain [13]. Hence, we
made the hypothesis of a possible involvement of both viruses in
MS pathogenesis, with the possibility for MSRV of a direct role of
effector of pathogenicity, and for EBV of an initial trigger of future
MS, years later. This ‘‘dual virus hypothesis’’ has been done also
for torque teno virus [43], but an association between infection by
this ubiquitous virus and MS could not be established so far [44].
Aim of the present study was to verify whether HERV-W
activation by EBV might occur also in vivo, during a delayed
primary infection by EBV, in young adults with IM symptoms
requiring hospitalization. Indeed, the data indicate that the main
links between EBV and MS (IM and high anti-EBNA-IgG titers)




The study was approved by the Sassari ASL Ethics Committee
(Protocol number 1120/L). The patients and the volunteers gave
written informed consent. Written informed consent from the next
of kin (which was one of the parents in all cases) on the behalf of
minors (under the age of 18) was obtained.
Patients
Seventeen consecutive IM patients (mean age 23.265.7 years,
median 22, 13 females and 4 males), hospitalized in the Section of
HERV-W, EBV and Infectious Mononucleosis
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Infectious Diseases, Department of Clinical and Experimental
Medicine, University of Sassari, were enrolled. Laboratory
diagnosis of acute EBV infection was made by serological assays
confirming the presence of EBV viral capsid antigen (VCA) IgM
antibodies. For each patient, the data collected included type and
duration of symptoms, family history for autoimmune diseases,
including MS, neurological signs, routine IM-related clinical
symptoms and signs, hematological values, and any steroid
therapy. Serum EBV-specific IgG and IgM antibodies were
detected by commercially available Chemiluminescence Immu-
noassays (CLIA), following manifacturer’s instructions (LIAISONH
VCA IgG, IgM and EBNA-1 IgG, DiaSorin S.p.A. Vercelli, Italy).
In most patients EBV DNA was evaluated in the plasma by real-
time PCR (EBV ELITe MGBTM Kit, according to the manufac-
turer’s protocols. Twenty four matched healthy donors (HD, mean
age 26.264.8 years, median 25, 16 females and 8 males) were
included as controls. Nine of them were EBV-negative, while
fifteen had been infected by EBV previously. Of the latters, eight
individuals had high levels of IgG antibody to the Epstein-Barr
nuclear antigens (EBNA-1 IgG, titers .600 IU/ml). On Table 1
the most relevant demographic and clinical characteristics of
hospitalized IM patients and of healthy controls are reported.
Blood Cell Separation
Peripheral blood mononuclear cells (PBMC) were isolated from
heparinized peripheral blood samples by layering on Ficoll/
Hipaque, as described [27]. Cell viability was assessed with the
Trypan blue exclusion method. The cells were either frozen in
deep cold, or processed immediately for further studies (see below).
RNA Extraction and Real-time RT-PCR
The polyA+ RNAs were extracted from 50.000 cells, by mRNA
DynabeadsH kit (Dynal Biotech, Oslo, NO) and retrotranscribed,
as described [13]. Selective amplification of the MSRV-type
HERV-Wenv transcripts was obtained by a discriminatory real
time RT-PCR assay, as published in [45]. The RNA amounts used
for retrotranscription were 1.5 mg/sample, and the PCR temper-
ature was 60uC. The quantification of cDNA sequences was
obtained by external calibration curves, obtained from serial
dilutions of plasmids containing the amplicon of interest (10–105
copies/well), as described previously [18]. The TaqManH
MSRVenv probe was designed by the Beacon Designer software
(PREMIER Biosoft International CorinaWay Palo Alto, CA). To
control for correct amplification and retrotranscription, a positive
sample was also submitted to each RNA extraction procedure, and
the resulting extract was amplified in triplicate. Parallel RNA
samples were also exposed to PCR amplification without the RT
step, to detect contaminant DNA. Prevention measures against
cross-contamination were employed. For each sample, the Ct
(cycle threshold) value of the gene of interest (GI) was normalized
by comparison to the Ct of the glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) invariate housekeeping gene, assuming
that: (i) a difference of 1 between sample Cts means that the
sample with the lower Ct value had double the target sequence of
the other sample, and (ii) the rate of Ct change versus the rate of
target copy change is identical for the gene of interest and the
housekeeping gene. housekeeping gene. The data have been






Aliquots of 250,000 alive PBMC were employed for each
evaluation. The detection of HERV-Wenv protein on the plasma
membrane, as well as the phenotype of PBMC subpopulations,
were performed by flow cytometry as described [13]. Briefly, the
detection of HERV-Wenv protein on the plasma membrane was
performed using anti-HERV-Wenv rabbit polyclonal antibody
(Allele Biotec, 2 mg/sample, for 20 minutes at room temperature
in the dark) and secondary fluorescein isothiocyanate-conjugated
goat anti-rabbit IgG (Sigma-Aldrich). The isotype control was a
pre-immune rabbit serum (Santa Cruz Biotechnology, Inc). To
determine the phenotype of cell subpopulations, the PBMC were
stained for 20 minutes at room temperature in the dark with
allophycocyanin-conjugate anti-CD14, phycoerythrin-conjugated
anti-CD19, and peridinin-chlorophyll-conjugated anti-CD16 an-
tibodies (BD Biosciences). As isotype control, an anti-rabbit IgG
antibody was used (Santa Cruz Biotechnology, Inc). Cells were
analysed on a FACS Calibur flow cytometer, using Cells Quest
software (Becton-Dickinson). The area of positivity was deter-
mined using an isotype-matched antibody; a total of at least 50,000
events for each sample were acquired.
Statistical Analysis
Descriptive statistics included mean, median, standard deviation
(SD), interquartile range. The Shapiro-Wilks test was used to
check the normality of the distribution. Between-group differences
were assessed by using Kruskall Wallis and Mann–Whitney U-test
for continuous nonnormally distributed variables, as appropriate.
The relationship between nonparametric variables were evaluated




Blood samples of patients hospitalized with laboratory-con-
firmed diagnosis of IM were collected during the acute phase.
Mean disease duration at the time of blood collection was
16.8611.9 days from onset of symptoms, median 12 days, range
5–55 days. Eightytwo percent of the patients was in the first two
weeks from IM onset, when the major immunologic and
virological changes during primary EBV infection occur [46].
None of the patients or healthy controls had recognized risk of
MS. The main characteristics of the study participants are
reported on Table 1.
Expression of MSRVenv Transcripts
The relative quantification of MSRVenv transcripts in PBMC
of patients and controls was carried out by MSRVtype-specific
real-time RT-PCR [45]. Normalysed data are reported on
Figure 1: there is a statistically significant increase of MSRVenv
transcripts in whole PBMC from IM patients with respect to
healthy subjects (the median of IM patients is 6.9 fold higher than
the one of healthy donors, p = 0.014).
Since high titers of anti-EBNA antibodies have been associated
with increased risk of MS [35,40], the healthy donors were
stratified according to their anti-EBNA-1 IgG titers, as uninfected
HERV-W, EBV and Infectious Mononucleosis
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(negative), or previously infected with low or high anti-EBNA-
1 IgG titers (below or above 600 IU/ml of plasma, respectively).
The data reported on Figure 1B indicate that the amounts of
MSRVenv mRNA present in PBMC of healthy individuals are
strictly related to those of anti-EBNA-1 IgG (p= 0.0005). Howev-
er, the highest MSRVenv mRNA values are observed in the blood
of IM patients, i.e. during the acute, highly symptomatic phase of
the primary infection. In facts, the MSRVenv mRNA median
value of IM patients is 194-fold higher that of uninfected persons;
the values of persons with high and low anti-EBNA-1 IgG titers
















IM-1 18 M 5 38.5 .160 80 neg 115 ,185
IM-2 23 F 8 40 .160 126 neg blb neg
IM-3 19 F 9 38.5 106 neg neg neg ndc
IM-4 20 F 10 39 .160 146 neg .150 nd
IM-5 23 F 10 37.5 .160 35 neg bl neg
IM-6 32 F 10 38 .160 33 bl neg 5,725
IM-7 22 F 10 37.5 83 119 neg 104 nd
IM-8 22 F 12 39 .160 195 bl 69 neg
IM-9 23 M 12 39 115 231 neg .150 1,685
IM-10 23 F 15 38.5 49 21 neg neg 225
IM-11 21 F 16 38 .160 58 bl 65 ,185
IM-12 14 F 17 39 .160 108 neg .150 180
IM-13 22 F 18 38 Pos pos pos bl nd
IM-14 27 M 19 38.5 .160 58 neg 54 401
IM-15 19 F 23 38.2 .160 neg neg neg nd
IM-16 40 M 37 39.5 95 neg neg neg neg
IM-17 27 F 55 37.5 .160 345 .600 .150 neg
HD-1 20 F – – Neg neg neg neg nd
HD-2 21 F – – Neg neg neg neg nd
HD-3 22 F – – Neg neg neg neg nd
HD-4 23 F – – Neg neg neg neg nd
HD-5 23 F – – Neg neg neg neg nd
HD-6 27 F – – Neg neg neg neg nd
HD-7 31 F – – Neg neg neg neg nd
HD-8 31 M – – Neg neg neg neg nd
HD-9 32 F – – Neg neg neg neg nd
HD-10 20 M – – Neg 483 157 neg nd
HD-11 21 M – – Neg 137 246 neg nd
HD-12 23 F – – Neg 158 48 nd nd
HD-13 23 F – – Neg 143 142 neg nd
HD-14 26 M – – Neg nd ,600 nd nd
HD-15 28 M – – Neg 81,3 289 neg nd
HD-16 29 F – – Neg nd ,600 nd nd
HD-17 23 F – – Neg nd .600 nd nd
HD-18 23 F – – Neg nd .600 nd nd
HD-19 25 F – – Neg .750 .600 neg nd
HD-20 26 M – – Neg .750 .600 neg nd
HD-21 29 F – – Neg .750 .600 neg nd
HD-22 29 M – – Neg 176 .600 neg nd
HD-23 35 F – – Neg neg .600 neg nd
HD-24 39 M – – Neg nd .600 nd nd
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are 131- and 28-fold, respectively, the MSRVenv mRNA levels of
uninfected persons, with high statistical significance.
Presence of the HERV-Wenv Protein on the Plasma
Membrane
Due to the high percentage of identities between the HERV-
Wenv genes, no antibody specific for a unique HERV-Wenv
protein has been identified so far [13]. Therefore it cannot be
discriminated whether an env protein is a MSRV-type env or
syncytin-1, and data must be expressed as HERV-Wenv positivity
only. Alive PBMC of four IM patients were analyzed by flow
cytometry in comparison to four EBV-negative healthy individuals
and four persons with past (latent) EBV infection and high anti-
EBNA-1 IgG titers, with respect to the presence of HERV-Wenv
protein on the outer surface of the plasma membrane. The
analysis was limited to four individuals for each group, in order to
compare only values collected in the same session, to avoid
technical variations. The results are reported on Figure 2. As
shown on Figure 2A, in whole PBMC the HERV-Wenv positivity
of IM patients and of persons with past EBV infection is almost
twice that of EBV-negative subjects. The HERV-Wenv protein,
however, is not uniformly exposed by all the PBMC, but derives
from an uneven expression in the various cell subsets. No statistical
significance is reached in Figure 2A, since the main component of
PBMC is the T cell compartment, that was previously shown to be
totally negative for HERV-Wenv expression, both at the protein
and at the RNA level [13,47]; therefore it was not analysed
specifically. However, no HERV-Wenv expression was detected
on the plasma membrane of CD192/CD162/CD142 cells, that
comprises the T cells (data not shown). As shown in Panels 2B–D,
in uninfected individuals the median HERV-Wenv positivity of
CD19+, CD16+ and CD14+ cells (B lymphocytes, NK cells and
monocytes, respectively) is around 19, 10 and 17%, respectively.
The env positivity of the CD19+ B cell compartment (Figure 2B) is
more than doubled after EBV infection (IM patients: 43%, latently
infected highly anti-EBNA-1 positive individuals: 56%, p= 0.043).
As for the CD16+ NK cell subset (Figure 2C), there is a 4-fold
increase in HERV-Wenv expression during IM (40%, p= 0.020),
but a deep reduction in latently infected highly anti-EBNA-1
positive individuals: 3%). The CD14+ monocyte compartment
(Figure 2D) showed the highest increases of HERV-Wenv
expression: 5.4-fold increase during IM (mean positivity: 92%,
p= 0.043) and 2.6-fold increase during highly anti-EBNA-1
positive latency (44%); also the difference between the latter two
group reaches the statistical difference (p= 0.021).
Discussion
A history of IM and high anti-EBV titers are factors that
increase the risk of MS [5,7–8,35–38,40]. The mechanism by
which EBV infection is linked to MS pathogenesis is still unknown
[4,30–31]. No studies support unequivocally a direct etiologic role
of EBV or prove its preferential presence, expression or
reactivation in MS patients with respect to controls to MS, and
currently there is no consensus in establishing whether there is a
presence of EBV-infected cells in the CNS of MS patients[30,41–
42]. Therefore, it remains to be determined whether EBV would
continue to play a role after disease initiation.
On the other hand, potentially neuropathogenic endogenous
retroviruses of the W family are expressed in the blood and in the
brain of MS patients in close parallelism with disease progression
[23,26–27]. Recently we have found a link between EBV and
HERV-W, since we showed that the binding in vitro to the
plasmamembrane of the EBVgp350 major envelope protein is able
to activate the expression of the potentially immunopathogenic
and neuropathogenic HERV-Ws in in cells that may be involved
in MS pathogenesis (B cells, monocytes, macrophages and
astrocytes) [13]. Hence, we made the dual virus hypothesis of a
possible involvement of both viruses in MS pathogenesis, with the
possibility for MSRV of a direct role of effector of pathogenicity,
and for EBV of an initial trigger of future MS, years later.
In the present report, we provide for the first time data showing
that activation of HERV-W/MSRV occurs in vivo in patients
affected by IM. With respect to EBV-negative healthy controls, the
increase of MSRV-type env mRNAs in IM patients is almost 2
Log10 (p = 0.000006, Figure 1B). More interestingly, when healthy
controls are stratified with respect to previous EBV infection (high
and low, or no anti-EBNA-1 IgG titers), a close correlation occurs
for MSRV mRNA activation (Sperman rho= 0.60, p,0.05).
Figure 1. MSRV-type mRNA expression by PBMC from IM patients and healthy donors (HD). The amounts of MSRV-type HERV-Wenv
transcripts were evaluated by discriminatory real time RT-PCR, and normalized by the 22DCt method (see Methods for details). Data are expressed as
medians (line), with maximum and minimum values (whiskers); boxes represent interquartile range of the samples. Statistical significance was
evaluated by the Mann-Whitney U-test for comparison of two groups, and by the Kruskal-Wallis test for three or four groups. (A) Comparison of IM
patients (N = 17) and all healthy donors (HD, N= 24). (B) Comparison of IM patients (N = 17) and HD donors stratified according to plasmatic anti-
EBNA-1 IgG titers, as EBV-negative (EBV2, N = 9), ,600 IU/ml (N = 7), and .600 IU/ml (N = 8). Kruskall-Wallis test gave p= 0.0005 for all four groups,
and p= 0.014 for the three HD groups.
doi:10.1371/journal.pone.0078474.g001
HERV-W, EBV and Infectious Mononucleosis
PLOS ONE | www.plosone.org 5 November 2013 | Volume 8 | Issue 11 | e78474
These novel findings are reinforced by the flow cytometry data
on the activation also of the HERV-Wenv protein product,
reported in Figure 2 as the percentage of PBMC expressing the
HERV-Wenv protein on the membrane. The HERV-W activa-
tion is not uniform in all cell subtypes nor in acute disease and past
infection, i.e. the latency state (Figures 2B–D). With respect to
uninfected healthy individuals, IM patients showed a doubling of
HERV-W positivity of B cells, and 4-fold and 5.5-fold increases in
NK cells and monocytes, respectively. In past infection with high
anti-EBNA-1 IgG titers, B cells continue to express similar
HERV-Wenv levels, while the effect is reduced on monocytes
(2.6-fold higher than in uninfected individuals), and NK cells
became almost HERV-Wenv-negative. We have no explanation
for the latter finding. On the whole, the data indicate that post-
transcriptional regulation of HERV-Wenv occurs differently in
specific cell subsets, in keeping with our previous observations
[13].
Thus in our hands both ascertained links between EBV and risk
of future MS (IM and high anti-EBNA-1 titers) do stimulate the
expression of HERV-W/MSRV.
As for the mechanisms of HERV-W activation, we showed
recently that in vitro EBV activates HERV-W/MSRV/syncytin-1,
in cells from blood and brain, that might be involved in the
pathogenesis of MS [13]. There is no need of EBV entry or
expression, since the effect was seen also after exposure to the
EBVgp350 major envelope protein. In EBVgp350-treated PBMC,
MSRVenv and syncytin-1 transcription was activated in B cells and
monocytes, but not in T cells (that do not express HERV-W
genes), nor in the highly positive NK cells. The latter cells (as the
monocytes and the B, but not the T cells) were activated by
proinflammatory cytokines, likely with involvement of the protein
kinase C signalling enzyme [13]. The effect of EBVgp350 was
abolished by silencing NF-kB, a transcription factor that is
implicated in the production, by activated astrocytes, of pro-
inflammatory cytokines: this, in turn, induces further release of
cytokines, that contribute in vivo to exacerbating the neurodegen-
erative process [48], and that in vitro stimulate HERV-Wenv
expression in astrocytes (unpublished data) and PBMC [13,49]. It
is likely that in vivo, during EBV replication in IM patients, the
EBVgp350 protein could activate HERV-W/MSRV expression,
as we showed in vitro [13]. In addition, a cytokine-mediated
mechanism could cooperate with EBV for HERV-W activation.
As known, several cytokines are produced during acute IM. In a
prospective study of late primary EBV infections, Balfour et al.
[46], detected elevated levels of eight cytokines that might
contribute to IM pathogenesis, among which interferonc, TNFa,
and IL-6; the latter was correlated significantly with IM severity
and high EBV viremia. Of note, IL-6 is a major cytokine in the
central nervous system, that has been related to many brain
diseases, among which MS [50]. The above cytokines do increase
HERV-W expression/release in vitro [13,49], and are increased
in vivo during MS exacerbations [50].
Figure 2. Presence of HERV-Wenv protein on the plasma membrane of PBMC subpopulations from IM patients and controls. Flow
cytometry evaluation of alive PBMC from IM patients (IM) and healthy donors (HD), either with anti-EBNA-1 IgG titers .600 IU/ml or EBV2 negative
(EBV2). Data were evaluated as percentage of cells with HERV-Wenv-specific staining, as specified in Methods, and are expressed as medians (line),
with maximum and minimum values (whiskers); boxes represent interquartile range of the samples. Statistical significance was evaluated by the
Mann-Whitney U test for comparison of two groups. When not specified, differences were not significant. All samples (four for each group) were
evaluated in the same day. (A) Comparison of HERV-W-specific staining of whole PBMC. (B), (C), (D) HERV-W-specific staining of PBMC
subpopulations sorted by specific staining with anti-CD19, anti-CD16 and anti-CD14 antibodies, respectively.
doi:10.1371/journal.pone.0078474.g002
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Of particular interest is the effect of EBV activation of HERV-
W/MSRV in the vast majority of monocytes during the acute
infection (Figure 2D, IM), for possible involvements in MS
pathogenesis. In vitro, these cells were shown to be the most
responsive to EBVgp350, reaching, after exposure to the EBV
protein, HERV-W levels higher than those detected in B cells,
particularly after cell differentiation into macrophages [13]. In MS
and other neurological diseases, significant infiltration of immune
cells from the periphery into the CNS (and activation of microglia)
is largely observed, and it accounts for the increased representa-
tion of macrophages within the CNS; the functions of activated
macrophages (and microglia) within the CNS are complex, as they
are implicated in both demyelination and remyelination of MS
lesions, as observed in animal models [51]. Increased blood-brain
barrier permeability is a characteristic hallmark of the CNS
alterations leading to MS, suggesting a causal relationship between
inflammatory cell recruitment into the CNS and the blood–brain
barrier dysfunction [52]. Activated monocytes easily pass across
the endothelia, and could carry the HERV-W across the blood-
brain barrier, entering the brain, where the HERV-Wenv protein
could contribute to the pathogenicity, inducing inflammation,
demyelination and axonal damage [6,10–13]. Thus, the HERV-W
expression (and release) by monocyte-macrophages can reasonably
account for the bulk of expression (and effects) of these elements.
Also the high levels of HERV-W expression in B cells throughout
the IM and the post-infection stages (Figure 2B), as well as in MS
patients [13] might contribute to the process, since B cells have
been proposed to be relevant to the etiology and pathogenesis of
MS [53], and MS therapies targeting B cells seem effective against
the relapsing-remitting forms [54].
As for the post-infection stages of EBV latency, it is well known
that during latency, EBV expresses a limited repertoire of proteins,
non-coding RNAs and microRNAs [54]. The virus remains
immunologically silent in small numbers of memory B cells, which
traffic into inflamed tissues, and are tightly controlled by invariant
natural killer T cells [55] and by cytotoxic T lymphocyte cells to
prevent lymphoproliferation [56]. Since HERV-W is expressed by
a high proportion of B cells (Figure 2B), it is likely that reciprocal
interactions occur within these cells during latency, that could play
an additional role to the indirect mechanism proposed by Meier
and coworkers, by which latent EBV infection could contribute to
(neuro)inflammation, through the expression of small non-coding
RNAs that bind to Toll-like receptor 3 and potentially other
intracellular receptors [56]. Notably, EBNA-1 is the only viral
protein commonly expressed in latency programs that allow the
persistence of EBV in B-cells during activation and differentiation
and in a variety of other cells types, and this protein has been
shown to reprogram cellular transcription and signaling [58–59].
Moreover, its binding to several cellular promoters has been
documented [60]. Therefore a contribute of EBNA-1 to HERV-W
activation in these cells could be hypothesized, either by direct
HERV-W activation in circulating B cells, or indirectly, through
induction of HERV-W-activating stimuli. A major issue of the
present paper is not only the finding that HERV-W is activated
during IM, but also that it is observed in a subset of healthy,
latently-infected individuals (those with antiEBNA-1 titers .600).
A long prospective study showed that elevations of antibody titers
to the EBNA complex and EBNA-1 among MS cases first
occurred between 15 to 20 years before the onset of symptoms and
persisted thereafter [57]. We show here that high HERV-W
expression occurs in healthy persons with high anti-EBNA Ig
titers, thus concomitantly to what has been considered among the
early events in the pathological process that leads to MS, perhaps
in individuals presenting a predisposing genetic background.
In conclusion, our data indicate that the two main links of EBV
to MS (past IM and high anti-EBNA-1 IgG titers) are associated to
the activation of potentially neuropathogenic HERV-W/MSRV,
both at the mRNA and the protein levels. These novel findings
reinforce our hypothesis of a possible involvement of both viruses
in MS pathogenesis [13], with the possibility for MSRV of a direct
role of effector of pathogenicity, and for EBV of an initial trigger of
future MS, years later, and indicate the activation of HERV-W/
MSRV as the possible missing link between EBV and MS. These
findings may open new avenues of intervention against MS.
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